In a dose-escalation study, how is the dose administered across groups?

• A. A fixed dose given to all participants
• B. A low dose is given to a small group, and then the dose is escalated in new groups until significant side effects occur
• C. Doses are randomly varied within the same subjects
• D. Doses are escalated only after pharmacologic effect is confirmed

Answer: (B)

In a dose-escalation study, safety guides the design: you start with a very low dose given to a small group (a cohort). If that dose is tolerated, you move to a new cohort that receives a higher dose. This stepwise escalation continues across successive groups until you observe dose-limiting toxicities or significant adverse effects, at which point escalation stops or the protocol is adjusted. This approach minimizes risk by not exposing many participants to high doses at once and helps map how increasing dose relates to safety and tolerability, ultimately helping identify a safe or maximum tolerated dose range.

This differs from giving a fixed dose to everyone, which doesn’t probe how higher doses might affect safety, and from randomizing varying doses within the same subjects, which isn’t how dose exploration is typically conducted. It’s also not primarily driven by waiting for pharmacologic effect confirmation; safety and tolerability across escalating cohorts guide the process.